Diagnostic Approach and Management of Pancytopenia with Splenomegaly

Initial Diagnostic Considerations

Peripheral blood smear review by a qualified hematologist is mandatory to identify characteristic cells that can establish or exclude specific diagnoses, particularly in patients with hairy cell leukemia, which is highly likely given the age, pancytopenia, and splenomegaly, according to the American Society of Hematology 1, 2.
Flow cytometry of peripheral blood should be performed immediately using anti-B-cell monoclonal antibodies to diagnose hairy cell leukemia, which is characterized by CD11c+, CD25+, CD103+, and CD123+ cells with strong CD200 expression, as recommended by the European Society for Medical Oncology 2.
Bone marrow aspirate and biopsy with flow cytometry and cytogenetics are essential, particularly in patients over 60 years with splenomegaly and cytopenias, to differentiate between myeloproliferative neoplasms, aplastic anemia, lymphoproliferative disorders, and infiltrative processes, according to the American College of Physicians 1, 3.

Hairy cell leukemia characteristically presents with splenomegaly, pancytopenia, and bone marrow involvement with fibrosis in patients with a median age of 52 years, and diagnosis is established by flow cytometry showing CD11c+, CD25+, CD103+, and CD123+ cells with strong CD200 expression, as stated by the National Comprehensive Cancer Network 2.
Primary myelofibrosis presents with marked hepatosplenomegaly, pancytopenia, and bone marrow fibrosis, often accompanied by constitutional symptoms, and bone marrow biopsy will show fibrosis, and peripheral smear may reveal leukoerythroblastic picture, according to the European Hematology Association 3, 4.

For anemia (hemoglobin <10 g/dL) in primary myelofibrosis, corticosteroids, androgens, danazol, or erythropoiesis-stimulating agents may be used, with response rates of 30-40%, as recommended by the American Society of Clinical Oncology 4, 5.
For symptomatic splenomegaly in primary myelofibrosis, hydroxyurea is the first-line treatment, achieving spleen volume reduction in approximately 40% of patients, according to the European Society for Medical Oncology 3, 4, 5.
Splenectomy may be considered for drug-refractory marked splenomegaly causing severe cachexia, symptomatic portal hypertension, or transfusion-dependent anemia, but carries 5-10% perioperative mortality and 50% complication rate, as stated by the Society of Surgical Oncology 6, 5.